Oncology Journal CME/CE

11.00 91.00
Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Blood September 21, 2023
A database study suggests that older patients with diffuse large B-cell lymphoma need more accessible, effective, and tolerable therapy.

$Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)$

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Prevalence and Clinical Expression of Germ Line Predisposition to Myeloid Neoplasms in Adults With Marrow Hypocellularity

Blood August 17, 2023
A cohort study shows the spectrum, symptoms, and prevalence of germline predisposition mutations in adults with cytopenia/hypoplastic bone marrow.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Spectrum of Clonal Hematopoiesis in VEXAS Syndrome

Blood July 21, 2023
UBA1^mut cells are the main cause of systemic inflammation/marrow failure in VEXAS, a new molecularly defined somatic entity linked to myelodysplastic syndrome (MDS).

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Phase 2 Clinical Trial Evaluating Abatacept in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Blood June 15, 2023
Abatacept’s safety, efficacy, and effect on the immune microenvironment in steroid-refractory cGVHD suggest it may be a promising treatment.

$Phase 2 Clinical Trial Evaluating Abatacept in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease$

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
The role of CD8+ T-cell clones in immune thrombocytopenia

Blood May 18, 2023
Targeting clonally expanded CD8+ T cells could be a novel therapeutic approach for refractory immune thrombocytopenia.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00
Autoimmune Hemolytic Anemia During Pregnancy and Puerperium: An International Multicenter Experience

Blood April 20, 2023
Autoimmune hemolytic anemia during pregnancy warrants vigilance, close monitoring, and prompt therapy to optimize outcomes.

1.00 CMEMIN

Save
10.50 90.50 20.50 30.50
Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents—Selected U.S. States, 2019

Morbidity & Mortality Weekly Report April 04, 2023
Clinicians should use quality care strategies and partner with sickle cell anemia (SCA) patients, families, and groups to reduce barriers to the prevention of stroke and other complications.

0.50 CME/CEMIN 0.50 ABIM MOCMIN 0.50 CEMIN 0.50 CEMIN

Save
11.00 91.00
Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but Monoallelic del(1p32) Remains a Strong Prognostic Factor

Blood March 16, 2023
In the era of risk-adapted treatment strategies, it is crucial to detect del(1p32) at multiple myeloma diagnosis, suggests a cytogenetic study.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Associations of Clonal Hematopoiesis With Recurrent Vascular Events and Death in Patients With Incident Ischemic Stroke

Blood February 16, 2023
Identifying genetic/other CH risk factors may improve personalized risk stratification and secondary prevention in ischemic stroke.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Long-Term Risk of Relapse in Immune-Mediated Thrombotic Thrombocytopenic Purpura and the Role of Anti-CD20 Therapy

Blood January 24, 2023
Lack of early iTTP relapse or treatment failure predictors mandates regular ADAMTS13 monitoring to prevent progression to clinical relapse.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Outcomes of Patients With Aggressive B-Cell Lymphoma After Failure of Anti-CD19 CAR T-Cell Therapy: A DESCAR-T Analysis

Blood December 15, 2022
Patients with R/R aggressive BCL-failing anti-CD-19 CAR T-cell therapy have an unmet medical need meriting further innovative strategy.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
The Role of Allogeneic Transplant for Adult Ph⁺ ALL in CR1 With Complete Molecular Remission: A Retrospective Analysis

Blood November 17, 2022
Adults with Ph⁺ ALL who achieved CMR within 3 months of starting treatment had lower incidence of disease relapse with allo-HCT in CR1.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save
11.00 91.00
Incidence and Impact of Anticoagulation-Associated Abnormal Menstrual Bleeding in Women After Venous Thromboembolism

Blood October 20, 2022
How prevalent is abnormal uterine bleeding in women with a new venous thromboembolism diagnosis? A new study provides data to help inform clinical decisions.

1.00 CMEMIN 1.00 ABIM MOCMIN

Save

No Results